This was a randomized, controlled, fourway crossover study in 45 subjects with a tendency to suffer from moderate heartburn following some meals. The study was designed to assess the time to onset of the perceived soothing and cooling effects of the alginate raft-forming products, Gaviscon Liquid (peppermint), Gaviscon Double Action Liquid (peppermint) and Gaviscon Powder Formulation (fresh tropical), compared with a non-active sublingual control. All three Gaviscon products provided significantly faster soothing and cooling effects compared with the control. Based on the upper 95% confidence limits for the median, time to onset of soothing was perceived within 3.15 min, 3.08 min and 4.05 min for Gaviscon Liquid, Double Action Liquid and Powder Formulation, respectively. Similarly, time to onset of cooling was perceived within 1.95 min, 1.23 min and 11.22 min for Gaviscon Liquid, Double Action Liquid and Powder Formulation, respectively. The results show that Gaviscon Liquid and Gaviscon Double Action soothe within 3.15 min and cool within 1.95 min.
Introduction
Many people experience symptoms of heartburn and regurgitation, indicative of gastro-oesophageal reflux disease, to a mildto-moderate extent in response to food. 1 This post-prandial heartburn is often related to specific food triggers such as fatty, spicy, rich or large meals. 2, 3 The sufferer, realizing the lifestyle-related nature of the symptoms and that they are not serious, tends not to consult their general practitioner (GP) but purchases an over-the-counter (OTC) medication to relieve the symptoms. 1, 4 OTC medications for the relief of heartburn include a wide variety of antacids for bulk neutralization of stomach acid, alginate reflux suppressants that form a raft to suppress reflux and also H 2 -receptor antagonists (H 2 RAs) and proton pump inhibitors (PPIs) that pharmacologically block/inhibit acid secretion.
The patient requires the OTC medication for rapid and effective control of the symptoms V Strugala, PW Dettmar, K Sarratt et al. Gaviscon for rapid relief of heartburn symptoms that they are experiencing. Antacids have a rapid but short-lived effect and H 2 RAs and PPIs, whilst highly effective, have a long latency before symptom relief is seen. 5, 6 In contrast, alginate raft-forming reflux suppressants have a rapid onset of action with prolonged control of symptoms. 7 -9 Subjectively, patients have reported the demulcent effects of cooling and soothing with alginate products but this has never been robustly evaluated. Techniques exist to evaluate the onset of subjective sensorial observations in short time frames using a stopwatch. 10 A pilot study was successfully carried out to show the validity of using this stopwatch technique in heartburn sufferers to assess the time to onset of soothing and cooling effects in response to treatment. 11, 12 The aim of the present study was to document robustly the time to onset of consumer-perceived soothing and cooling effects in the oesophagus after taking OTC alginate products, compared with a nonactive sublingual control, to treat postprandial heartburn. In order to do this a prospective, randomized, controlled, fourway crossover study was performed using a dual-stopwatch technique.
Subjects and methods

STUDY DESIGN
The study was a randomized, controlled, four-way crossover study in a single centre with partial blinding. A single dose of test drug was evaluated in subjects experiencing post-prandial heartburn. 
STUDY POPULATION
Subjects were recruited from the community who were 18 -65 years of age and experienced post-prandial heartburn but who were otherwise healthy and not receiving prescribed treatment for heartburn from their GP.
Each subject attended two screening visits (at least 48 h apart), the second of which was used to confirm the presence of moderate heartburn (assessed on a self-rating scale) within 60 min of consumption of a standard refluxogenic meal (60% fat). Subjects who met this criterion were invited to participate in the study.
Exclusion criteria were recent unexplained weight loss of 6 -7 kg in the last 6 months, gastrointestinal (GI) bleeding in the last 12 months, difficulty swallowing, history of (or symptoms suggestive of) Zollinger-Ellison syndrome, gastric carcinoma, peptic ulcer disease, pernicious anaemia, Barrett's oesophagus or systemic sclerosis, or receipt of treatment for reflux or upper GI conditions from their GP. Subjects using antacids, H 2 RAs, motility stimulants, prokinetics or other medicines for the relief of reflux within 24 h of screening visit 2 or PPIs within 48 h prior to screening visit 2 were also excluded.
Other exclusion criteria were hypophosphataemia, phenylketonuria, severe constipation or colonic stenosis, intolerance or allergy to the study drugs or formulation constituents (sodium alginate, calcium carbonate, sodium bicarbonate, parabens), lactose, soya or wheat, and patients who were on steroids or non-steroidal antiinflammatory drugs. In addition, subjects with a history of cardiovascular disorders, V Strugala, PW Dettmar, K Sarratt et al. Gaviscon for rapid relief of heartburn symptoms drug, solvent and alcohol abuse, or with diabetes were excluded, as were pregnant or lactating women or those who were seeking to get pregnant, as well as subjects who, in the opinion of the study investigator, were unable to comply with the study requirements.
STUDY PROTOCOL
Subjects who satisfied the inclusion criteria attended the study unit at 08:00 h on four separate occasions (2 -7 days between visits) and received a light breakfast before fasting for 4 h. At the first visit, subjects were allocated a study number and randomized to one of four schedules for allocating treatments to visits based on a Latin Square design. Subjects were given a standard refluxogenic meal comprising 60% fat and asked to lie in a supine position after the meal and until they experienced heartburn of at least moderate severity on a self-rating scale. At this point they were changed to a sitting position and dosed with their randomly allocated study medication for that visit. The subjects were provided with two stopwatches that were started by the study staff at the time of dosing. One was to record the time to first perception of a soothing effect in the throat/oesophagus and the other to record the time to first perception of a cooling effect in the throat/oesophagus. Subjects were instructed to stop the stopwatch when the relevant effect was perceived. If no feeling of soothing/cooling was perceived within 30 min the result was censored at 30 min. Subjects failing to report heartburn within 60 min of the meal were not dosed.
At the end of the 30-min treatment period, the subject was asked if they would be willing to use the product again, if they would be willing to replace their current OTC therapy and if they experienced any adverse events.
A post-study visit took place 3 -7 days after the last treatment to check on any adverse events that may have been experienced by the subjects post-treatment.
TEST PRODUCTS
The four study drugs were provided by Reckitt Benckiser Healthcare (UK) Ltd Investigational Material Supplies Unit (Hull, UK) and were as follows: Gaviscon Liquid (GL) -peppermint (500 mg sodium alginate, 267 mg sodium bicarbonate, 160 mg calcium carbonate per 10 ml liquid dose); Gaviscon Double Action Liquid (GDAL)peppermint (500 mg sodium alginate, 213 mg sodium bicarbonate, 325 mg calcium carbonate per 10 ml liquid dose); Gaviscon Powder Formulation (GPF) -fresh tropical (500 mg sodium alginate, 267 mg sodium bicarbonate, 160 mg calcium carbonate per 1.428 g sachet powder dose); and non-active sublingual control tablet (50.1 mg lactose, 30 mg mannitol per 100 mg sublingual tablet dose). The control sublingual tablet was not a placebo in the strictest sense of the word since the format and appearance was different to the test products. This format was chosen as it was unlikely to provide a soothing or cooling effect upon the oesophagus. Gaviscon products were provided in a blinded fashion to both subjects and study staff although, due to the difference in formulation, the control sublingual tablet was administered openlabel.
DETERMINATION OF SAMPLE SIZE
A pilot study was performed using 20 subjects with a four-way crossover format to evaluate the methodology. 11, 12 Post-hoc review of the data using Kaplan-Meier methods showed that the median time of onset of soothing was 1.37 min for GL and 1.17 min for GDAL. The Kaplan-Meier V Strugala, PW Dettmar, K Sarratt et al. Gaviscon for rapid relief of heartburn symptoms medians for time of onset of cooling were 0.57 min for GL and 0.45 min for GDAL. Although methods do not exist to assess the power of a study to provide Kaplan-Meier medians with a prospectively defined level of precision, it was considered that a study with 40 subjects would be sufficient to substantiate the claims 'soothes within 3 min' and 'cools within 2 min' for GL and GDAL and, potentially, for GPF (the latter was not tested in the pilot study). Post-study review of the data for the pilot study also indicated that a study in 40 subjects would have > 90% power to demonstrate that the times to onset of soothing and cooling were statistically shorter for the Gaviscon products compared with the control using Kaplan-Meier survival analysis methodology.
STATISTICAL ANALYSIS
Times to first perceived soothing and cooling effects were recorded. Minimum and maximum values as well as mean ± SD were calculated and the number of censored measurements recorded. The Kaplan-Meier medians and their 95% confidence intervals (CI) were calculated for each parameter and treatment. Comparison between treatments was performed using a Cox regression model adjusted for repeated events. The design factors, treatment sequence and study period were included in this model. An overall comparison of the difference in the times to first perception of soothing and cooling between treatment groups was analysed using analysis of variance (ANOVA) and pairwise comparisons between active treatments and the control.
Answers to yes/no questions were compared using a χ 2 -test for independence, and pairwise comparison between treatments and control were evaluated, if deemed appropriate. A P-value < 0.05 was considered to be statistically significant. Statistical analysis was performed using the software package SAS version 9.1.3 (SAS Institute Inc., Charlotte, NC, USA) for Windows ® .
Results
SUBJECT DEMOGRAPHICS
Sixty-four subjects were screened; 45 demonstrated moderate heartburn in response to a refluxogenic meal at screening visit 2 and were randomized to participate in the study. The study population comprised 17 males and 28 females of mean ± SD age 35.7 ± 11.2 years. All subjects were Caucasian apart from one African-Caribbean. Mean ± SD height was 169.5 ± 10.6 cm, weight was 75.8 ± 16.3 kg and body mass index was 26.2 ± 4.0 kg/m 2 . One subject was withdrawn prior to dosing at treatment visit 3 for a positive screen for drug use (having received two treatments) and one subject did not experience heartburn on the fourth treatment visit and so did not receive the final scheduled treatment. Data collected for these two patients for visits prior to their withdrawal were included in the analysis.
TIME TO FIRST PERCEPTION OF SOOTHING
Efficacy data for the time to first perception of a soothing effect in the throat/oesophagus following dosing of each of the four study drugs are presented in Table 1 . In the majority of subjects, the control drug did not generate a soothing effect, with 70% having results censored at 30 min. All subjects perceived soothing within 30 min for GDAL and GPF, but two subjects (4.5%) failed to report soothing within 30 min with GL. The Kaplan-Meier median time to first perception of soothing was 2.26 min for GL, 2.12 min for GDAL and 2.97 min for GPF. Soothing was noted for all Gaviscon V Strugala, PW Dettmar, K Sarratt et al. Fig. 1A shows the Kaplan-Meier curves for the four products. Based on the upper 95% CI for the median times of onset, perception of soothing in the throat/oesophagus during an episode of heartburn occurred within 3.15 min for GL, 3.08 min for GDAL and 4.05 min for GPF. According to ANOVA, a significant overall difference in time to first perception of soothing was noted between treatments (P < 0.0001). Pairwise comparison revealed that the time to first perception of soothing was significantly shorter for all three Gaviscon products compared with the control (all P < 0.0001). 
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TIME TO FIRST PERCEPTION OF COOLING
Efficacy data for the time to first perception of a cooling effect in the throat/oesophagus are presented in Table 1 . In the majority of subjects, the control drug did not generate a cooling effect, with 75% having results censored at 30 min. All subjects perceived cooling within 30 min for GDAL, but four subjects (9%) failed to feel cooling with GL and 14 subjects (31%) failed to perceive cooling with GPF. Kaplan-Meier median time to first perception of cooling was 1.08 min for GL, 0.83 min for GDAL and 3.95 min for GPF. Cooling was noted for all Gaviscon products, within a median (Kaplan-Meier analysis) of 4 min of dosing. Fig. 1B displays the Kaplan-Meier curves for all four products. Based on the upper 95% CI for the median times of onset, a perception of cooling in the throat/oesophagus during an episode of heartburn was observed within 1.95 min for GL, 1.23 min for GDAL and 11.22 min for GPF. According to ANOVA, a significant overall difference in time to first perception of cooling was noted between treatments (P < 0.0001). Pairwise comparison revealed that the time to first perception of cooling was significantly shorter for all three Gaviscon products compared with the control (all P < 0.0001).
SECONDARY ENDPOINTS
When assessed, a significantly greater proportion of subjects stated that they would be willing to use the product again for the three Gaviscon products compared with the control (GL 79.5%, GDAL 93.2%, GPF 51.1%, control 6.8%; P < 0.0001 versus control in each case). Similarly, when asked whether they would be willing to replace their current OTC therapy with the test product there was a significantly greater proportion willing to do so for all the Gaviscon products compared with the control (GL 38.6%, GDAL 56.8%, GPF 26.7%, control 2.3%; P < 0.05 versus control in each case). It must be noted that no record of their current therapy was made or whether they were regular users of Gaviscon products, although patients prescribed therapy by their GP were excluded from the study, so current therapies would have been self-administered OTC products.
SAFETY EVALUATION
Twelve subjects reported a total of 13 treatment emergent adverse events. One occurred after treatment with GL, three after treatment with GDAL, five after treatment with GPF and four after treatment with the control. Four events were mild, eight were moderate and one was classed as severe (headache) but all resolved with no sequelae. Eleven adverse events were deemed to be not related to or unlikely to be related to the study medication. One event (abdominal pain) was classified as possibly related to study medication (GPF) and one event (flatulence) as probably related to the study medication (GDAL). There were no serious adverse events.
Discussion
The present study was a randomized, controlled trial with four treatment arms carried out in a crossover format such that each subject was evaluated after receiving all four treatments. It was a sensorial study to assess subjectively the onset of perceived demulcent effects of soothing and cooling after using products for the treatment of heartburn that was instigated by consumption of a refluxogenic meal. A pilot study had previously shown the validity of using a dual-stopwatch method in the heartburn indication, and in this study format, in order to record the time to first perception of soothing or cooling in response V Strugala, PW Dettmar, K Sarratt et al. Gaviscon for rapid relief of heartburn symptoms to the medication. 11, 12 Subjects were able to distinguish clearly between the sensorial effects of soothing and cooling.
In the present study, three OTC Gaviscon product variants were evaluated compared with a non-active sublingual control tablet in 45 subjects. The control sublingual tablet was not a placebo in the strictest sense of the word since the format and appearance was different to the test product. This format was chosen for the control as it was unlikely to provide a soothing or cooling effect upon the oesophagus; however, this difference in formulation meant that blinding of the investigators and study subjects to the control tablet was not feasible. In all cases, the times to first perception of soothing and cooling were significantly faster with the Gaviscon products compared with the control.
Gaviscon products have been described as having a rapid onset of action in comparison with H 2 RAs and PPIs over the first hour after dosing using objective measures of reflux. 7 It has, however, been suggested by the manufacturers and users of Gaviscon products that relief of symptoms can be identified rapidly (in a matter of minutes) in subjective assessment. The present study was designed to substantiate the claims of 'soothes within x minutes' and 'cools within y minutes' and to generate robust data as to the time to onset of these sensorial effects.
Based on the upper 95% CI for the median times of onset, this study showed that for GL a perception of soothing in the throat/oesophagus during an episode of heartburn was observed within 3.15 min, while cooling was perceived within 1.95 min. GDAL, which has additional acid neutralization capacity, 13 demonstrated a slightly quicker onset of both soothing and cooling compared with GL (soothing in 3.08 min and cooling in 1.23 min). GPF was less effective, achieving soothing within 4.05 min and cooling only within 11.22 min. The impact of cooling may be related to the peppermint flavouring in the liquid formulations and the known cooling effect of menthol. 14 The limitations of the present study were, first, that due to formulation constraints, full blinding was not possible and as a result investigators and study subjects were blinded to the active Gaviscon drugs but not the inactive sublingual control. Secondly, the subjects' current OTC therapy was not recorded, which goes some way to explaining the low response to the secondary endpoint question regarding willingness to replace current therapy with the evaluated treatment.
Reflux causes an irritant action upon the oesophagus leading to the burning and painful sensation of heartburn. A perception of soothing in the oesophagus may, therefore, indicate the cessation of the irritant effect upon the oesophageal mucosa. This demulcent effect in the oesophagus following ingestion of Gaviscon products demonstrates a rapid local mode of action upon dosing prior to generation of the alginate raft within the stomach, the primary mode of action. 15 A demulcent effect has been previously reported, based upon a subjective assessment of throat pain on swallowing in response to a product, thereby justifying such a claim for Gaviscon products. 16 In conclusion, this randomized, controlled, four-way crossover trial has shown that the three Gaviscon products tested provided a significantly faster onset of action compared with the non-active control compound in terms of perceived soothing and cooling effects within the oesophagus. The GL (peppermint) and GDAL (peppermint) formulations can provide a
